Newsroom Subscribe Contact
About us
About us
Our Science
Our Science
Pipeline
Pipeline
Investors
Investors

News & Media Coverage

Press Releases
Featured multimedia
Media coverage
Media contact
News alerts

Press Releases

October 3, 2023
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
September 27, 2023
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
September 20, 2023
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
September 18, 2023
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
September 11, 2023
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
September 5, 2023
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
August 30, 2023
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
August 28, 2023
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
August 28, 2023
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
August 21, 2023
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
August 14, 2023
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
July 24, 2023
Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
July 17, 2023
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
June 26, 2023
Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing
June 12, 2023
Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
June 7, 2023
Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
June 5, 2023
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
May 30, 2023
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
May 24, 2023
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
May 22, 2023
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
May 19, 2023
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
May 18, 2023
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
May 15, 2023
Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights
May 2, 2023
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month
April 10, 2023
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
April 3, 2023
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
March 23, 2023
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
March 21, 2023
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications
March 14, 2023
Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery
February 28, 2023
Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 23, 2023
Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 22, 2023
Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference
February 1, 2023
Enveric Biosciences to Present at the BIO CEO & Investor Conference
December 21, 2022
Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during “J.P. Morgan Health Care Week 2023”
November 28, 2022
Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders
November 16, 2022
Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference
November 1, 2022
Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022
October 24, 2022
Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies
October 12, 2022
Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference
August 31, 2022
Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
July 27, 2022
Enveric Biosciences Appoints New Independent Directors
July 26, 2022
Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules
July 25, 2022
Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules
July 19, 2022
Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines
July 14, 2022
Enveric Biosciences Announces Reverse Stock Split
July 13, 2022
Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio
June 8, 2022
Enveric Biosciences to Participate in Upcoming Conferences in June 2022
May 24, 2022
Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022
May 17, 2022
Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022
May 11, 2022
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
May 5, 2022
Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET
May 3, 2022
Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
April 6, 2022
Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022
March 31, 2022
Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update
March 29, 2022
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application
March 15, 2022
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
March 3, 2022
Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022
March 1, 2022
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
February 17, 2022
Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress
February 15, 2022
Enveric Biosciences Announces Closing of $10 Million Public Offering
February 11, 2022
Enveric Biosciences Announces Pricing of $10 Million Public Offering
February 8, 2022
Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 – Cannabinoid + Celecoxib Conjugate
January 27, 2022
Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022
January 18, 2022
Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders
January 6, 2022
Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
December 6, 2021
Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer
November 18, 2021
Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate
November 8, 2021
Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF
October 26, 2021
Enveric Biosciences to Participate in Wonderland: Miami Conference
October 7, 2021
Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021
October 5, 2021
Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its ‘Psybrary’ of Psychedelic Molecular Compounds
September 20, 2021
Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021
September 17, 2021
Enveric Biosciences Announces Closing of MagicMed Industries Acquisition
September 9, 2021
Enveric Biosciences Announces MagicMed Industries’ Presentations at the Following Investor Conferences in September
August 18, 2021
Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders
July 8, 2021
Enveric Biosciences Announces Approval from Israel’s Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma
June 3, 2021
Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences
May 24, 2021
Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives
May 18, 2021
Enveric Biosciences Reports First Quarter 2021 Financial Results
May 12, 2021
Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board
April 14, 2021
Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st
April 12, 2021
Enveric Biosciences Appoints Carter Ward as Chief Financial Officer
April 1, 2021
Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021
March 18, 2021
Enveric Biosciences Appoints Dr. Douglas D. Lind to Company’s Board of Directors
March 15, 2021
Enveric Biosciences to Participate in Upcoming Investor Conferences in March
March 10, 2021
Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech
February 25, 2021
Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs
February 12, 2021
Enveric Biosciences Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock
February 9, 2021
Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering
January 19, 2021
Enveric Biosciences Issues Shareholder Letter Providing Strategic Vision for Advancing Novel Prescription Supportive Care Cancer Therapies
January 15, 2021
Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering
January 12, 2021
Enveric Biosciences Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 5, 2021
Enveric Biosciences Appoints Dr. Marcus Schabacker to Board of Directors

Featured multimedia

April 26, 2023
Fireside with Enveric Biosciences – Benzinga Psychedelics Capital Conference April 2023
October 21, 2022
Enveric Biosciences Company Overview Video
 Anxiety Disorders
May 11, 2022
NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics
May 11, 2022
CEO Update: Enveric to Spin-off and Dividend Cannabinoid Pipeline to Shareholders

Media coverage

October 2, 2023
Biotech firm receives patent for psilocybin-derived mental health therapeutics [Helio]
October 2, 2023
Psilocybin-Based Drug Candidate Gains Patent [High Times]
September 22, 2023
U.S. approval for psychedelic drug MDMA nears after success in clinic [Labiotech]
September 22, 2023
Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here [Benzinga]
September 20, 2023
Enveric Receives Patent For Psilocybin Molecules [Green Market Report]
May 11, 2022
NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics
April 19, 2022
Enveric Offers Investors Rare Exposure To Both Cannabis And Psychedelic Industries [Benzinga]
March 31, 2022
Bob Dagher, Chief Medical Officer at Enveric Biosciences [The Green Rush]
March 29, 2022
Inside the Race to Make Psychedelics ‘Mainstream Medicines’ [Endpoints News]
March 24, 2022
Five Companies Developing Second Generation Psychedelics For Mental Health [Benzinga]
February 21, 2022
Groundbreaking Trial to Explore Psychedelic Therapy for Cancer Distress [Psychedelic Health]
February 17, 2022
Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary [via Benzinga]
February 17, 2022
UCalgary to Collaborate on Clinical Trial Assessing Psychedelic Treatments and Cancer Related Distress [The Edmonton Journal]
February 8, 2022
Enveric Biosciences Files Provisional Patent for Cannabinoid + Celecoxib Conjugate EV104 after Successful Synthesis [IPO Edge]
February 8, 2022
Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis [Benzinga]
January 28, 2022
How AI Could Unlock the Medical Potential of Psychedelics
January 24, 2022
Here’s What Happens When Psychedelics Meets AI [Green Market Report]
January 24, 2022
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of [Vice]
December 15, 2021
Enveric Names New Chief Medical Officer [Green Market Report]
December 12, 2021
This Isn’t the 60s Again’: Psychedelics Business Takes Off Amid Culture Clash [The Guardian]
December 3, 2021
What Did You Miss at This Year’s Wonderland Psychedelic Conference? [Cannabis & Tech Today]
November 18, 2021
Enveric Biosciences’ CBD-Based Product Reduces Dermatitis Severity In Animal Study [Benzinga]
November 16, 2021
CBD News Roundup: Study Shows Effectiveness of CBDistillery Sleep Product [CBD Insider]
November 16, 2021
Enveric Biosciences Sees Opportunity In Both Cannabinoids, Psychedelics [Green Market Report]
October 25, 2021
Highlights on Enveric Biosciences [Psychedelic Spotlight]
July 12, 2021
Enveric Enters Next Phase Of CBD Cancer Treatment Trial [Candid Chronicle]
July 8, 2021
Enveric Biosciences and MagicMed [The Green Rush Podcast]
June 29, 2021
Enveric Biosciences – Clinical Development of Cannabinoids and Psychedelics [Health Professionals Radio]
June 23, 2021
Texas the Latest State to Legalize Psychedelic Medical Research [Bloomberg Law]
June 9, 2021
Enveric Biosciences + MagicMed on Recent Acquisition Announcement, Mind and Body Clinical Pipeline [SNN]
June 4, 2021
Exclusive: MagicMed CEO On Psychedelics Company’s ‘Secret Sauce,’ M&A Deal With Enveric Biosciences [Benzinga]
May 28, 2021
Psyched: Nasdaq Gets Its Third Psychedelics Company, Mynd Goes Public, Delic Buys New Research Facility [Benzinga]
May 24, 2021
Another Psychedelics Company Joins ‘Exclusive Nasdaq Group’ With Enveric’s Acquisition Of MagicMed Industries [Benzinga]
May 24, 2021
MagicMed to Be Acquired by Nasdaq-Listed Company [Psilocybin Alpha]
May 24, 2021
Enveric Biosciences Buys MagicMed In All Stock Deal Valued At $30 Million [The Green Market Journal]
May 24, 2021
MagicMed: Finding the Derivative with Dr. Joseph Tucker [Psychedelic Invest]
May 24, 2021
Enveric Biosciences Acquires Psychedelic Drug Discovery Platform MagicMed Industries [Psychedelic Spotlight]
May 24, 2021
Enveric Moves to Acquire MagicMed, Form Latest Nasdaq-Listed Psychedelics Company [Truffle Report]
May 24, 2021
Enveric Biosciences Buys MagicMed In All Inventory Deal Valued At $30 Million [Marijuana Mag]
April 13, 2021
Oncology Peer Review On-The-Go: 1-on-1 with David Johnson: Enveric’s Endocannabinoid Products for Glioblastoma [Cancer Network]
April 13, 2021
Happy Employees = Happy Shareholders [Fortune]
April 7, 2021
Enveric Biosciences CEO Describes How the Group Has ‘Multiple Shots on Goal’ with Current Pipeline [Proactive Investors]
March 25, 2021
David Johnson, Chairman and CEO of Enveric Biosciences [The Green Rush Podcast]
March 24, 2021
Enveric’s Patient-Centric Model to Enhance the Quality of Life of Cancer Patients [Benzinga]
March 17, 2021
Enveric Biosciences on Acquisition of Exclusive License from Diverse Biotech and Value Catalysts [SNN]
March 11, 2021
Enveric Biosciences Acquires License for Diverse Biotech’s Novel Molecules [Pharmaceutical Technology]
March 11, 2021
Enveric Biosciences Signs Licensing Agreement with Diverse Biotech [Pharmaceutical Business Review]
March 10, 2021
CBD-focused Enveric Biosciences Stock Soars on Heavy Volume After License Deal with Cancer Treatment Company [Market Watch]
March 10, 2021
Enveric Biosciences Stock Skyrockets After Licensing Agreement With Diverse Biotech [Benzinga]
February 11, 2021
Rising High: An Exclusive Talk with Biotech Company Enveric Biosciences [The Fly]
February 4, 2021
Cannabis Stocks Rally Anew as $7 Billion GW Pharma Deal Spurs Interest in Weed and its Medical Benefits [MarketWatch]
February 4, 2021
Jazz Leaps into Epilepsy with $7.2B Buyout of Cannabinoid Drugmaker GW Pharma [Fierce pharma]
April 5, 2019
Medical cannabinoids (CBD) and brain tumours – Interview with Dr. Wai Liu (via Brain Tumour Research)
February 19, 2019
Cannabis Executives Reveal The Industry’s 2019 Challenges And A Few Opportunities Too
October 5, 2018
Cannabidiol (CBD) oil as a treatment for brain tumours (via Brain Tumour Research)
November 2, 2017
Dr. Wai Liu and the effect of cannabis on cancer (via ITV News)
June 6, 2017
Marijuana destroys leukemia cells, says totally chill new study (via Maxim)
June 6, 2017
A compound in cannabis is ‘significantly’ effective in destroying cancerous tumours in leukaemia, study reveals (via The Daily Mail)
June 5, 2017
Cannabinoids shown to enhance tumor-killing effects of chemotherapy drugs (via New Atlas)
June 5, 2017
Cannabinoids used in sequence with chemotherapy are a more effective treatment for cancer, say experts (via Science Daily)
November 18, 2014
How pot helped shrink one of the most aggressive brain cancers (via The Washington Post)
November 14, 2014
How cannabis was used to shrink one of the most aggressive brain cancers (via The Conversation)
March 3, 2013
Research into cannabinoids’ anti-cancer potential in Britain (via Charlotte Foot)

Casey McDonald
Tiberend Strategic Advisors, Inc.
(646) 577-8520
cmcdonald@tiberend.com

Subscribe to Receive News Alerts